Up In Smoke: Pfizer’s Chantix Sales Go Poof

[Guest guest]

Up In Smoke: Pfizer's Chantix Sales Go Poof 8 Comments By Ed Silverman // July 23rd, 2008 // 8:21 am

The smoking-cessation drug isn't ringing the register, thanks to months of bad publicity and regulatory warnings, although this should hardly come as a surprise. In its earnings report, Pfizer notes that Chantix revenues in the second-quarter were $207 million, an increase of just 3 percent compared with the same period a year earlier.

In the US, specifically, Chantix revenues fell 35 percent to $109 million, although international sales rose 197 percent to $98 million. To compensate, Pfizer vows to continue educational and promotional efforts focused on the Chantix "risk-benefit proposition" and the health consequences of smoking. Meanwhile, overseas marketing is expanding. Known as Champix overseas, the drug was just launched in Japan and will soon debut in Russia, Turkey, China and six other countries over the next year

http://www.pharmalot.com/page/2/

[Guest guest]

Up In Smoke: Pfizer's Chantix Sales Go Poof 8 Comments By Ed Silverman // July 23rd, 2008 // 8:21 am

The smoking-cessation drug isn't ringing the register, thanks to months of bad publicity and regulatory warnings, although this should hardly come as a surprise. In its earnings report, Pfizer notes that Chantix revenues in the second-quarter were $207 million, an increase of just 3 percent compared with the same period a year earlier.

In the US, specifically, Chantix revenues fell 35 percent to $109 million, although international sales rose 197 percent to $98 million. To compensate, Pfizer vows to continue educational and promotional efforts focused on the Chantix "risk-benefit proposition" and the health consequences of smoking. Meanwhile, overseas marketing is expanding. Known as Champix overseas, the drug was just launched in Japan and will soon debut in Russia, Turkey, China and six other countries over the next year

http://www.pharmalot.com/page/2/

[Guest guest]

Up In Smoke: Pfizer's Chantix Sales Go Poof 8 Comments By Ed Silverman // July 23rd, 2008 // 8:21 am

The smoking-cessation drug isn't ringing the register, thanks to months of bad publicity and regulatory warnings, although this should hardly come as a surprise. In its earnings report, Pfizer notes that Chantix revenues in the second-quarter were $207 million, an increase of just 3 percent compared with the same period a year earlier.

In the US, specifically, Chantix revenues fell 35 percent to $109 million, although international sales rose 197 percent to $98 million. To compensate, Pfizer vows to continue educational and promotional efforts focused on the Chantix "risk-benefit proposition" and the health consequences of smoking. Meanwhile, overseas marketing is expanding. Known as Champix overseas, the drug was just launched in Japan and will soon debut in Russia, Turkey, China and six other countries over the next year

http://www.pharmalot.com/page/2/

[Guest guest]

Up In Smoke: Pfizer's Chantix Sales Go Poof 8 Comments By Ed Silverman // July 23rd, 2008 // 8:21 am

The smoking-cessation drug isn't ringing the register, thanks to months of bad publicity and regulatory warnings, although this should hardly come as a surprise. In its earnings report, Pfizer notes that Chantix revenues in the second-quarter were $207 million, an increase of just 3 percent compared with the same period a year earlier.

In the US, specifically, Chantix revenues fell 35 percent to $109 million, although international sales rose 197 percent to $98 million. To compensate, Pfizer vows to continue educational and promotional efforts focused on the Chantix "risk-benefit proposition" and the health consequences of smoking. Meanwhile, overseas marketing is expanding. Known as Champix overseas, the drug was just launched in Japan and will soon debut in Russia, Turkey, China and six other countries over the next year

http://www.pharmalot.com/page/2/